lancastotug (AK127) / Akesobio - LARVOL DELTA

A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1 | N=205 | Recruiting | Sponsor: Akeso | Phase classification: P1a/1b ➔ P1

Phase classification • Oncology • Solid Tumor

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours (clinicaltrials.gov) - P1 | N=66 | Active, not recruiting | Sponsor: Akesobio Australia Pty Ltd | Recruiting ➔ Active, not recruiting | N=143 ➔ 66 | Trial primary completion date: Jan 2025 ➔ Oct 2024

Combination therapy • Enrollment change • Enrollment closed • Metastases • Trial primary completion date • Oncology • Solid Tumor

A Phase Ib/II Study of AK112 (PD-1/VEGF Bispecific Antibody) in Combination Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC). (clinicaltrials.gov) - P1/2 | N=280 | Not yet recruiting | Sponsor: Akeso

Combination therapy • Metastases • New P1/2 trial • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours (clinicaltrials.gov) - P1 | N=143 | Recruiting | Sponsor: Akesobio Australia Pty Ltd | Phase classification: P1a/1b ➔ P1

Combination therapy • Metastases • Phase classification • Oncology • Solid Tumor

A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1a/1b | N=205 | Recruiting | Sponsor: Akeso | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Oncology • Solid Tumor

A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=216 | Not yet recruiting | Sponsor: Akeso

New P1/2 trial • Oncology • Solid Tumor

A Study of AK127 Combined With AK104 in Patients With Advanced Malignant Tumors (clinicaltrials.gov) - P1a/1b | N=205 | Not yet recruiting | Sponsor: Akeso

Combination therapy • Metastases • New P1 trial • Oncology • Solid Tumor

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours (clinicaltrials.gov) - P1a/1b | N=143 | Recruiting | Sponsor: Akesobio Australia Pty Ltd | Not yet recruiting ➔ Recruiting | Trial completion date: May 2023 ➔ Apr 2025 | Trial primary completion date: Mar 2023 ➔ Jan 2025

Combination therapy • Enrollment open • Metastases • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Akeso

Monotherapy • New P1 trial • Oncology • Solid Tumor

Akeso is rapidly advancing the clinical study of the PD-1/CTLA-4 bispecific antibody Cadonilimab combined with TIGIT monoclonal antibody for the teratment of solid tumors (PRNewswire-Asia) - "Akeso...announces that the first patient was dosed in a phase I clinical trial of the Company's independently developed TIGIT monoclonal antibody (AK127) in combination with the Company's global first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody,AK104) for the treatment of advanced or metastatic solid tumors in Australia. This is an open-label, multicenter phase I clinical trial designed to evaluate the safety, tolerability, pharmacokinetic, immunogenicity, pharmacodynamics and anti-tumor activity of AK127 in combination with Cadonilimab in subjects with advanced or metastatic solid tumors."

Trial status • Oncology • Solid Tumor

A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid Tumours (clinicaltrials.gov) - P1a/1b; N=143; Not yet recruiting; Sponsor: Akeso

Clinical • Combination therapy • New P1 trial • Oncology • Solid Tumor